New strategies for active immunotherapy with genetically engineered tumor cells

Research output: Contribution to journalArticlepeer-review

Abstract

While previous tumor vaccine strategies have shown intriguing results, clearcut efficacy has been difficult to establish in human trials. Recently, newer approaches have been developed in animal systems that modify tumor cells genetically so that they express new antigens or secrete certain cytokines. Engineering tumor cells to secrete cytokines in a paracrine fashion can induce powerful local cytokine effects without producing significant systemic toxicity. In addition to local inflammation, this approach can alter the presentation of tumor antigen or activation of tumor antigen-specific T lymphocytes, resulting in systemic antitumor immunity.

Original languageEnglish (US)
Pages (from-to)619-623
Number of pages5
JournalCurrent Opinion in Immunology
Volume4
Issue number5
DOIs
StatePublished - 1992

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'New strategies for active immunotherapy with genetically engineered tumor cells'. Together they form a unique fingerprint.

Cite this